IQ Medical is on a rocket ship—first-half 2026 revenue jumped 45% to $1.8M, fueled by doctors using ProSense more, not just buying more systems. With a 70% surge in U.S. installed base since FDA clearance for early-stage breast cancer, they’re expanding sales and going global. The CHOICE study is central: hospitals pay for probes while feeding real-world data that validates use—and drives adoption. Clinical wins include strong 5-year kidney cancer results and growing recognition from top medical societies, even potential inclusion in national guidelines. With $12M cash on hand, IQ Medical has the fuel to scale this integrated growth engine.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
